Patents by Inventor Joong Myung Cho

Joong Myung Cho has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210346321
    Abstract: The present invention relates to a pharmaceutical composition containing an alkyl carbamoyl naphthalenyloxy octenoyl hydroxyamide phosphate compound (hereinafter referred to as CG200745PPA) or a derivative thereof, and can provide a pharmaceutical composition in a tablet, granule, powder, capsule, dry syrup or injection form. By providing the composition in various forms, a suitable form can be selected and easily applied when oral administration is difficult.
    Type: Application
    Filed: October 28, 2019
    Publication date: November 11, 2021
    Inventors: Jae Pyoung CHO, Joong Myung CHO
  • Publication number: 20210113515
    Abstract: The present invention relates to a composite agent comprising polmacoxib and pregabalin. The present invention relates to a pharmaceutical composition and a drug or pain reliever, which each comprise the two active ingredients of polmacoxib and pregabalin and, more particularly, to a drug or pain reliever for treatment of moderately severe, acute, chronic, or neuropathic pain attributed to inflammation and various factors, an effect thereof, and a use thereof.
    Type: Application
    Filed: March 20, 2019
    Publication date: April 22, 2021
    Inventors: Jae Pyoung CHO, Joong Myung CHO
  • Publication number: 20210015772
    Abstract: The present invention relates to a pharmaceutical composition comprising alkylcarbamoyl naphthalenyloxy octenoyl hydroxyamide, a derivative thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for prevention or treatment of fibrosis. Effectively suppressing the proliferation of fibrous tissues, the composition can be used for preventing and/or treating fibrosis.
    Type: Application
    Filed: March 28, 2019
    Publication date: January 21, 2021
    Inventors: Joong Myung CHO, Jae Pyoung CHO, Hyunju CHA, Young-Dae KIM
  • Publication number: 20210009565
    Abstract: The present invention provides a compound selected from the group consisting of a compound of formula (I), pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates and isomers thereof; a use of the compound for the treatment, relief or prevention of diseases caused by absormal or uncontrolled activation of protein kinase, and a use of the compound for the manufacture of a medicament for the treatment, relief or prevention of the diseases; a pharmaceutical composition comprising the compound as an active ingredient; and a method for the treatment, relief or prevention of the diseases using the compound. The inventive compound is useful for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase.
    Type: Application
    Filed: February 14, 2020
    Publication date: January 14, 2021
    Inventors: Yong Rae HONG, Jeong Eun NA, Im Sook MIN, Hyun Ju CHA, Sool Ki KWON, Seonggu RO, Joong Myung CHO
  • Publication number: 20200283371
    Abstract: The present invention relates to a pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxyamide or of a derivative thereof and a method for preparing same, and can improve moisture stability while maintaining the characteristics, such as the efficacy and effective dose, of a pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxyamide or of a derivative thereof. In addition, the present invention can simplify the production and manufacturing process of a formulation by improving hygroscopicity.
    Type: Application
    Filed: April 18, 2018
    Publication date: September 10, 2020
    Inventors: Jae Pyoung Cho, Yong Ho Jung, Joong Myung Cho
  • Publication number: 20200276152
    Abstract: The present invention relates to a complex comprising polmacoxib and tramadol. The present invention relates to a pharmaceutical composition and a medicine or an analgesic, all of which contain two types of active ingredients of polmacoxib and tramadol, and, more specifically, to effects and uses of the active ingredients in a medicine or an analgesic for the treatment of moderate acute and chronic pain caused by inflammatory and multiple factors.
    Type: Application
    Filed: June 8, 2018
    Publication date: September 3, 2020
    Inventors: Jae Pyoung CHO, Hyunjin PARK, Joong Myung CHO
  • Patent number: 10604508
    Abstract: The present invention provides a compound selected from the group consisting of a compound of formula (I), pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates and isomers thereof; a use of the compound for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase, and a use of the compound for the manufacture of a medicament for the treatment, relief or prevention of the diseases; a pharmaceutical composition comprising the compound as an active ingredient; and a method for the treatment, relief or prevention of the diseases using the compound. The inventive compound is useful for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: March 31, 2020
    Assignee: CrystalGenomics, Inc.
    Inventors: Yong Rae Hong, Jeong Eun Na, Im Sook Min, Hyun Ju Cha, Sool Ki Kwon, Seonggu Ro, Joong Myung Cho
  • Patent number: 10413520
    Abstract: The present invention relates to a pharmaceutical composition including (i) as a major ingredient, a novel 5-{4-(Aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone compound (Formula 1) or a pharmaceutically acceptable salt thereof, which has a crystalline form A or G, or a mixed form thereof and has a 50% volume particle diameter (d(0.5)) of 3 ?m to 9 ?m and a 90% volume particle diameter (d(0.9)) of 10 ?m to 50 ?m, (ii) a pharmaceutically acceptable diluent, and (iii) a pharmaceutically acceptable lubricant. The pharmaceutical composition of the present invention has the advantages of good stability, high dissolution rate, improved content uniformity, and excellent pharmacokinetic properties. Due to these advantages, as a non-steroidal anti-inflammatory drug, the pharmaceutical composition of the present invention may be effective in treating inflammation or pain.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: September 17, 2019
    Assignee: CRYSTALGENOMICS, INC.
    Inventors: Byung-Ha Kim, Sik II Ahn, Jae-Yeon Park, Tae Ryong Kim, Joong Myung Cho, Seonggu Ro
  • Publication number: 20180344702
    Abstract: The present disclosure comprises a method for administering 2,3-dihydro-isoindole-1-one compound or a pharmaceutically acceptable salt, ester, solvate and/or prodrug thereof, for the treatment of hematological cancers such as acute myeloid leukemia (AML). The present disclosure further relates to reducing or inhibiting cell-proliferation which is activated by wild-type or mutated Fms-like tyrosine kinase-3 receptor (FLT3). The present disclosure further relates to a method of inhibiting or reducing abnormal (e.g., overexpressed) wild-type or mutated BTK activity or expression in a subject in need thereof.
    Type: Application
    Filed: February 21, 2018
    Publication date: December 6, 2018
    Applicants: Aptose Biosciences Inc., CrystalGenomics, Inc.
    Inventors: William G. RICE, Joong Myung CHO, Yongrae HONG
  • Publication number: 20180008571
    Abstract: The present invention relates to a pharmaceutical composition including (i) as a major ingredient, a novel 5-{4-(Aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone compound (Formula 1) or a pharmaceutically acceptable salt thereof, which has a crystalline form A or G, or a mixed form thereof and has a 50% volume particle diameter (d(0.5)) of 3 ?m to 9 ?m and a 90% volume particle diameter (d(0.9)) of 10 ?m to 50 ?m, (ii) a pharmaceutically acceptable diluent, and (iii) a pharmaceutically acceptable lubricant. The pharmaceutical composition of the present invention has the advantages of good stability, high dissolution rate, improved content uniformity, and excellent pharmacokinetic properties. Due to these advantages, as a non-steroidal anti-inflammatory drug, the pharmaceutical composition of the present invention may be effective in treating inflammation or pain.
    Type: Application
    Filed: June 22, 2017
    Publication date: January 11, 2018
    Inventors: Byung-Ha KIM, Sik II AHN, Jae-Yeon PARK, Tae Ryong KIM, Joong Myung CHO, Seonggu RO
  • Publication number: 20170362205
    Abstract: The present invention provides a compound selected from the group consisting of a compound of formula (I), pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates and isomers thereof; a use of the compound for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase, and a use of the compound for the manufacture of a medicament for the treatment, relief or prevention of the diseases; a pharmaceutical composition comprising the compound as an active ingredient; and a method for the treatment, relief or prevention of the diseases using the compound. The inventive compound is useful for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase.
    Type: Application
    Filed: August 30, 2017
    Publication date: December 21, 2017
    Inventors: Yong Rae Hong, Jeong Eun Na, Im Sook Min, Hyun Ju Cha, Sool Ki Kwon, Seonggu Ro, Joong Myung Cho
  • Patent number: 9758508
    Abstract: The present invention provides a compound selected from the group consisting of a compound of formula (I), pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates and isomers thereof; a use of the compound for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase, and a use of the compound for the manufacture of a medicament for the treatment, relief or prevention of the diseases; a pharmaceutical composition comprising the compound as an active ingredient; and a method for the treatment, relief or prevention of the diseases using the compound. The inventive compound is useful for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: September 12, 2017
    Assignee: CrystalGenomics, Inc.
    Inventors: Yong Rae Hong, Jeong Eun Na, Im Sook Min, Hyun Ju Cha, Sool Ki Kwon, Seonggu Ro, Joong Myung Cho
  • Publication number: 20170000759
    Abstract: The present invention relates to a pharmaceutical composition including (i) the compound of Formula 1 described in the specification or a pharmaceutically acceptable salt thereof, (ii) a pharmaceutically acceptable diluent, and (iii) a pharmaceutically acceptable lubricant. The compound of Formula 1 or pharmaceutically acceptable salt thereof has a 50% volume particle diameter (d(0.5)) of 3 ?m to 9 ?m. The pharmaceutical composition of the present invention has the advantages of good stability, high dissolution rate, improved content uniformity, and excellent pharmacokinetic properties. Due to these advantages, the pharmaceutical composition of the present invention is effective in treating inflammation or pain.
    Type: Application
    Filed: January 29, 2015
    Publication date: January 5, 2017
    Inventors: Byung-Ha KIM, Sik II AHN, Jae-Yeon PARK, Tae Ryong KIM, Joong Myung CHO, Seonggu RO
  • Publication number: 20150336934
    Abstract: The present invention provides a compound selected from the group consisting of a compound of formula (I), pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates and isomers thereof; a use of the compound for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase, and a use of the compound for the manufacture of a medicament for the treatment, relief or prevention of the diseases; a pharmaceutical composition comprising the compound as an active ingredient; and a method for the treatment, relief or prevention of the diseases using the compound. The inventive compound is useful for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase.
    Type: Application
    Filed: December 26, 2013
    Publication date: November 26, 2015
    Inventors: Yong Rae HONG, Jeong Eun NA, Im Sook MIN, Hyun Ju CHA, Sool Ki KWON, Seonggu RO, Joong Myung CHO
  • Patent number: 8053435
    Abstract: The present invention discloses novel naphthalenyloxypropenyl derivatives useful for inhibiting the enzyme activity of histone deacetylase, leading effective suppression of cancer cell proliferation.
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: November 8, 2011
    Assignees: Korea Research Institute of Chemical Technology, Crystalgenomics, Inc.
    Inventors: Cheol Hae Lee, Hee Jung Jung, Jae Hak Kim, Won Jang Jeong, Joong Myung Cho, Seong Gu Ro, Young Lan Hyun, Cheol Soon Lee, Dongkyu Shin
  • Patent number: 7973060
    Abstract: A compound which is effective for inhibiting Fab I, and a method for treating a bacterial infection.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: July 5, 2011
    Assignee: CrystalGenomics, Inc.
    Inventors: Cheol Min Kim, Dong Gyu Shin, Seonggu Ro, Joong Myung Cho, Young Lan Hyun
  • Publication number: 20110028507
    Abstract: Disclosed herein are pyridine derivatives, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, pharmaceutical compositions comprising the same, and methods of modulating the level or activity of HIF in a subject, inhibiting hydroxylation of HIF ? in a subject, modulating expression of HIF-regulated genes in a subject, treating an HIF-related disorder in a subject, increasing levels of endogenous EPO in a subject, or treating a disorder in a subject, using the disclosed compounds.
    Type: Application
    Filed: August 8, 2008
    Publication date: February 3, 2011
    Applicant: CRYSTALGENOMICS, INC.
    Inventors: Sun Nam Kim, Yong Rae Hong, Dongkyu Shin, Seonggu Ro, Joong Myung Cho, Mi Jung Lee, Ho Jin Chang
  • Publication number: 20100311965
    Abstract: An object of the present invention is to provide compounds which are useful as protein kinase inhibitors.
    Type: Application
    Filed: December 26, 2008
    Publication date: December 9, 2010
    Applicants: CARNA BIOSCIENCES INC., CRYSTAL GENOMICS, INC.
    Inventors: Masaaki Sawa, Koichi Yokota, Hideki Moriyama, Myoungyoup Shin, Seonggu Ro, Joong Myung Cho
  • Publication number: 20100069630
    Abstract: The present invention discloses novel naphthalenyloxypropenyl derivatives useful for inhibiting the enzyme activity of histone deacetylase, leading effective suppression of cancer cell proliferation.
    Type: Application
    Filed: November 1, 2007
    Publication date: March 18, 2010
    Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, CRYSTALGENOMICS, INC
    Inventors: Cheol Hae Lee, Hee Jung Jung, Jae Hak Kim, Won Jang Jeong, Joong Myung Cho, Seong Gu Ro, Young Lan Hyun, Cheol Soon Lee
  • Publication number: 20090170847
    Abstract: The inventive imidazopyridine derivative can be used in a pharmaceutical composition for preventing or treating diseases such as diabetes, obesity, dementia, cancer, and inflammation, since it can efficiently inhibit the activities of several protein kinases including glycogen synthase kinase-3 (GSK-3), aurora kinase, extracellular signal-regulated kinase (ERK), protein kinase B (AKT), and the likes, to control signal transductions thereof.
    Type: Application
    Filed: January 23, 2007
    Publication date: July 2, 2009
    Inventors: Seung Chul Lee, Jin Seok Choi, Jung Hoon Oh, Boonsaeng Park, Yong Eun Kim, Jun Hee Lee, Dongkyu Shin, Cheol Min Kim, Young-Lan Hyun, Cheol Soon Lee, Joong-Myung Cho, Seonggu Ro